BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36614290)

  • 21. A case of multiple gastrointestinal stromal tumors caused by a germline KIT gene mutation (p.Leu576Pro).
    Vale Rodrigues R; Santos F; Pereira da Silva J; Francisco I; Claro I; Albuquerque C; Lemos MM; Limbert M; Dias Pereira A
    Fam Cancer; 2017 Apr; 16(2):267-270. PubMed ID: 27771813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
    Woźniak A; Rutkowski P; Sciot R; Ruka W; Michej W; Debiec-Rychter M
    Int J Cancer; 2008 May; 122(9):2160-4. PubMed ID: 18183595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
    Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
    Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y.
    Thalheimer A; Schlemmer M; Bueter M; Merkelbach-Bruse S; Schildhaus HU; Buettner R; Hartung E; Thiede A; Meyer D; Fein M; Maroske J; Wardelmann E
    Am J Surg Pathol; 2008 Oct; 32(10):1560-5. PubMed ID: 18724244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of novel germline c-kit gene mutation, KIT-Tyr553Cys, observed in a family with multiple gastrointestinal stromal tumors.
    Nakai M; Hashikura Y; Ohkouchi M; Yamamura M; Akiyama T; Shiba K; Kajimoto N; Tsukamoto Y; Hao H; Isozaki K; Hirai T; Hirota S
    Lab Invest; 2012 Mar; 92(3):451-7. PubMed ID: 22083669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of various types of mast cells derived from model mice of familial gastrointestinal stromal tumors with KIT-Asp818Tyr mutation.
    Kajimoto N; Nakai N; Ohkouchi M; Hashikura Y; Liu-Kimura NN; Isozaki K; Hirota S
    Int J Clin Exp Pathol; 2015; 8(10):11970-82. PubMed ID: 26722383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
    Ali Abuderman AW; M Aldakheel F
    Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.
    Bachet JB; Landi B; Laurent-Puig P; Italiano A; Le Cesne A; Lévy P; Safar V; Duffaud F; Blay JY; Emile JF
    Eur J Cancer; 2013 Jul; 49(11):2531-41. PubMed ID: 23648119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sporadic somatic mutation of c-kit gene in a family with gastrointestinal stromal tumors without cutaneous hyperpigmentation.
    Yeh CN; Chen TW; Jan YY
    World J Gastroenterol; 2006 Mar; 12(11):1813-5. PubMed ID: 16586562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastrointestinal stromal tumors with exon 8 c-kit gene mutation might occur at extragastric sites and have metastasis-prone nature.
    Ito T; Yamamura M; Hirai T; Ishikawa T; Kanda T; Nakai T; Ohkouchi M; Hashikura Y; Isozaki K; Hirota S
    Int J Clin Exp Pathol; 2014; 7(11):8024-31. PubMed ID: 25550846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.
    Graham J; Debiec-Rychter M; Corless CL; Reid R; Davidson R; White JD
    Arch Pathol Lab Med; 2007 Sep; 131(9):1393-6. PubMed ID: 17824795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
    Yang W; Li K; Yu J; Shou C; Zhang Q; Hong Y; Sun J; Yu H; Gao Y; Shen Q; Zhao Z; Zheng S
    Scand J Gastroenterol; 2018; 53(10-11):1328-1334. PubMed ID: 30346846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
    Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
    Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial Gastrointestinal Stromal Tumor with Germline
    Sekido Y; Ohigashi S; Takahashi T; Hayashi N; Suzuki K; Hirota S
    Anticancer Res; 2017 Mar; 37(3):1425-1431. PubMed ID: 28314314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing.
    Künstlinger H; Huss S; Merkelbach-Bruse S; Binot E; Kleine MA; Loeser H; Mittler J; Hartmann W; Hohenberger P; Reichardt P; Büttner R; Wardelmann E; Schildhaus HU
    Am J Surg Pathol; 2013 Nov; 37(11):1648-59. PubMed ID: 24061512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
    Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
    Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
    Li J; Gao J; Hong J; Shen L
    Future Oncol; 2012 May; 8(5):617-24. PubMed ID: 22646775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.